Can You Lose With Covered Calls?
A balanced life… it’s what we all want right? You want balance in your diet, in your relationships, and in your news. That last one… Read More »Can You Lose With Covered Calls?
Alex Clarke
Continued Demand For Packaged Food Amid Delta Could Make This Stock A Sweet Deal – Literally.
In the face of the delta variant taking hold in the U.S., pandemic-driven demand for packaged foods could be sticking around for longer than had… Read More »Continued Demand For Packaged Food Amid Delta Could Make This Stock A Sweet Deal – Literally.
Does This Biopharma Company’s “Pipeline In A Drug” Cancer Therapy Make Its Stock A Buy?
The clinical-stage biopharmaceutical company discussed in today’s article, which is focused on developing innovative cancer therapies.
The “Delta Scare” Could Be A Great Opportunity To Get In On “The Explosive Small-Cap Energy” Story
COVID case numbers are surging again thanks the Delta variant, and concerns that this will result in more lockdowns and travel restrictions may be part of the reason for the recent pullback in oil and gas prices.
As We Enter The Second Inning Of The Pandemic, Could This “Dark Horse” COVID Vaccine Stock Win The Long Game?
With the fast-spreading Delta variant of the coronavirus taking hold in the U.S. and many countries around the world, we may just be entering the second inning of the COVID-19 pandemic.
An Effective Oral Therapy For COVID-19 Could Make This Under-The-Radar Biopharma Company A Big Winner
“With the more contagious delta variant now dominant in the U.S. despite the widespread availability of vaccines, the need for effective treatments is once again growing more urgent.”
3 Biotech Stocks To Watch As Cancer Treatments Remain A “Hotbed” For The Industry
“Cancer treatments have remained a hotbed for biotech companies.”
A Mid-Cap Opportunity In “Wet AMD”
The company’s drug for wet AMD had proven to help with the disorder, and thus it seems highly likely it will be approved.
Why The Coming Months Could Be A “Biotech Bonanza”
“It was a difficult first half for biotech stocks, once again underscoring how conditions may seem so ideal but investment returns can still be hard to generate.”
“Big Gains In A Short Time Frame”: 3 Potential Biotech Doublers
“Wall Street analysts following these biotechs have high expectations for the drugs they’re developing and in one case already marketing.